Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Crime boss Steven Lyons set to be deported from Bali to Spain - 2Minneapolis ICE shooting live updates: Protests continue over agent's killing of Renee Nicole Good; Walz puts National Guard on standby
- 3Jamie Dimon warns Iran war could drive inflation, interest rates higher
- 4Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how
- 5Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- Wedding trip Objections in Europe
- Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- Overhaul Your Rest: Tips for a Serene Evening
- Bavarian leader questions Germany's Eurovision participation
- US bishops officially ban gender-affirming care at Catholic hospitals
- Woman gives birth on roadside after hospital allegedly sent her home: Family
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
